OCULAR RISK FACTORS FOR RECURRENCE OF MYOPIC CHOROIDAL NEOVASCULARIZATION

• DOI: 10.1097/iae.0b013e318285cc24
• Publication Date: 2013-04-16T15:28:10Z
• Authors: Hae Min Kang; Hyoung Jun Koh
• Keywords: Adult; Male; Vascular Endothelial Growth Factor A; antivascular endothelial growth factor injection; Time Factors; Visual Acuity/physiology; Choroidal Neovascularization/diagnosis*; Visual Acuity; 610; Degenerative/diagnosis*; Angiogenesis Inhibitors; 03 medical and health sciences; 0302 clinical medicine; Recurrence; Risk Factors; Myopia; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Humans; Angiogenesis Inhibitors/therapeutic use; Fluorescein Angiography; Retrospective Studies; Choroidal Neovascularization/drug therapy; Degenerative/drug therapy; Middle Aged; myopic choroidal neovascularization; Choroidal Neovascularization; 3. Good health; photodynamic therapy; Photochemotherapy; Intravitreal Injections; Myopia, Degenerative; Female; Follow-Up Studies

To investigate factors associated with long-term recurrence of myopic choroidal neovascularization (CNV) after treatment photodynamic therapy (PDT) and/or intravitreal antivascular endothelial growth factor injections.Seventy-six eyes CNV completed at least a 48-month follow-up treatments. The baseline characteristics the were compared, including age, gender, refractive errors, axial lengths, location CNV, lacquer cracks, chorioretinal atrophy, dark rim, great linear dimension, and prior PDT.During mean 71.21 ± 26.43 months, 35 (46.1%) experienced 1 recurrence. Mean interval between initial first was 24.15 18.10 months. Presence crack (P = 0.022, χ(2) test), absence rim 0.031, PDT 0.041, test) significantly different without Among characteristics, presence (β 1.272, P 0.012) 1.607, 0.027), -0.758, 0.020) by multiple logistic regression.Long-term revealed in 46.1% patients treatment. PDT, risk for CNV.